TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Genenta Science SpA Sponsored ADR ( (GNTA) ) has shared an update.
On September 30, 2025, Genenta Science SpA announced the resignation of Dr. Carlo Russo as Chief Medical Officer and Head of Development due to personal reasons, with immediate effect. Dr. Francesco Galimi, a seasoned physician-executive with extensive experience in healthcare R&D, has been appointed as the acting Chief Medical Officer and Head of Development. This change in leadership is expected to bring new insights and direction to the company’s ongoing projects in the biotechnology sector.
The most recent analyst rating on (GNTA) stock is a Buy with a $21.00 price target. To see the full list of analyst forecasts on Genenta Science SpA Sponsored ADR stock, see the GNTA Stock Forecast page.
More about Genenta Science SpA Sponsored ADR
Genenta Science SpA is a biotechnology company involved in healthcare research and development, focusing on innovative therapies in the field of oncology.
Average Trading Volume: 9,321
Technical Sentiment Signal: Sell
Current Market Cap: $59.72M
For an in-depth examination of GNTA stock, go to TipRanks’ Overview page.